Want to see SNDX full AI Analyst Report?
Syndax Pharmaceuticals (SNDX) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Revumenib, Intensive Chemotherapy Regimen | Acute Myeloid Leukemias | Phase III | Not Yet Recruiting | Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation | Sep 30, 2025 | ― |
| Sndx-5613, Chemotherapy Regimen, Hidac | Acute Myeloid Leukemias | Phase I | Recruiting | A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias | Jan 12, 2024 | ― |
| Axatilimab | Idiopathic Pulmonary Fibrosis | Phase II | Recruiting | MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Nov 09, 2023 | ― |
| Chemotherapy, Revumenib | Solid Tumors, Colorectal Cancer | phase1AndPhase2 | Active Not Recruiting | Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors | Feb 07, 2023 | ― |
| Revumenib | Acute Leukemia | Phase I | Completed | Study of Radiolabeled Revumenib in Adults With Acute Leukemia | Jun 01, 2022 | ― |
| Axatilimab | Chronic Graft-Versus-Host-Disease | Phase II | Active Not Recruiting | A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) | Jan 05, 2021 | ― |
| Revumenib, Cobicistat | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia Of Ambiguous Lineage, Mixed Phenotype Acute Leukemia | phase1AndPhase2 | Recruiting | A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation | Aug 16, 2019 | ― |
| Axatilimab | Chronic Graft-Versus-Host-Disease | phase1AndPhase2 | Completed | A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD | Jul 10, 2018 | ― |
| Atezolizumab, Entinostat | Breast Cancer | phase1AndPhase2 | Completed | Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In | Mar 09, 2016 | ― |
| Pembrolizumab, Entinostat | Melanoma, Non-small Cell Lung Cancer, Mismatch Repair-Proficient Colorectal Cancer | phase1AndPhase2 | Completed | Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC) | Apr 27, 2015 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Revumenib, Intensive Chemotherapy Regimen | Phase III | Acute Myeloid Leukemias | Not Yet Recruiting | Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation | Sep 30, 2025 | ― |
| Sndx-5613, Chemotherapy Regimen, Hidac | Phase I | Acute Myeloid Leukemias | Recruiting | A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias | Jan 12, 2024 | ― |
| Axatilimab | Phase II | Idiopathic Pulmonary Fibrosis | Recruiting | MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Nov 09, 2023 | ― |
| Chemotherapy, Revumenib | phase1AndPhase2 | Solid Tumors, Colorectal Cancer | Active Not Recruiting | Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors | Feb 07, 2023 | ― |
| Revumenib | Phase I | Acute Leukemia | Completed | Study of Radiolabeled Revumenib in Adults With Acute Leukemia | Jun 01, 2022 | ― |
| Axatilimab | Phase II | Chronic Graft-Versus-Host-Disease | Active Not Recruiting | A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) | Jan 05, 2021 | ― |
| Revumenib, Cobicistat | phase1AndPhase2 | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia Of Ambiguous Lineage, Mixed Phenotype Acute Leukemia | Recruiting | A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation | Aug 16, 2019 | ― |
| Axatilimab | phase1AndPhase2 | Chronic Graft-Versus-Host-Disease | Completed | A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD | Jul 10, 2018 | ― |
| Atezolizumab, Entinostat | phase1AndPhase2 | Breast Cancer | Completed | Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In | Mar 09, 2016 | ― |
| Pembrolizumab, Entinostat | phase1AndPhase2 | Melanoma, Non-small Cell Lung Cancer, Mismatch Repair-Proficient Colorectal Cancer | Completed | Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC) | Apr 27, 2015 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Syndax Pharmaceuticals Inc. (SNDX) have in its pipeline
Syndax Pharmaceuticals SNDX is currently developing the following drugs: Revumenib, Intensive Chemotherapy Regimen, Sndx-5613, Chemotherapy Regimen, Hidac, Axatilimab, Chemotherapy, Revumenib, Revumenib, Revumenib, Cobicistat, Atezolizumab, Entinostat, Pembrolizumab, Entinostat. These drug candidates are in various stages of clinical development as the company works toward FDA approval.